AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.070
+0.010 (0.94%)
Jun 2, 2025, 11:08 AM - Market open

AN2 Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
14.2714.0714.7612.754.671.27
Upgrade
Research & Development
33.5240.4954.8729.5116.916.02
Upgrade
Operating Expenses
47.854.5569.6442.2621.577.28
Upgrade
Operating Income
-47.8-54.55-69.64-42.26-21.57-7.28
Upgrade
Interest & Investment Income
4.685.474.86-0.070
Upgrade
Currency Exchange Gain (Loss)
-----0.04-
Upgrade
Other Non Operating Income (Expenses)
-0-0.041.31--6.32
Upgrade
EBT Excluding Unusual Items
-43.12-49.09-64.73-40.96-21.54-13.6
Upgrade
Merger & Restructuring Charges
-2.23-2.23----
Upgrade
Pretax Income
-45.35-51.32-64.73-40.96-21.54-13.6
Upgrade
Net Income
-45.35-51.32-64.73-40.96-21.54-13.6
Upgrade
Preferred Dividends & Other Adjustments
---1.826.520.98
Upgrade
Net Income to Common
-45.35-51.32-64.73-42.78-28.06-14.58
Upgrade
Shares Outstanding (Basic)
3030241533
Upgrade
Shares Outstanding (Diluted)
3030241533
Upgrade
Shares Change (YoY)
14.15%26.39%53.85%481.46%2.71%0.61%
Upgrade
EPS (Basic)
-1.52-1.72-2.74-2.79-10.64-5.68
Upgrade
EPS (Diluted)
-1.52-1.72-2.74-2.79-10.64-5.68
Upgrade
EBIT
-47.8-54.55-69.64-42.26-21.57-7.28
Upgrade
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q